bluebird bio Inc (NASDAQ:BLUE)
| 6.86 BATS BZX Real-Time Price As of 11:06am ET |  +0.95 / +16.07%Today’s Change | 2.87 Today|||52-Week Range 17.85 | -31.33% Year-to-Date |
Latest BLUE News | Press Releases
| bluebird (BLUE) Q2 Loss Narrower Than Expected, Sales Miss Aug 05 / Zacks.com - Paid Partner Content | 1 Reason to Buy Bluebird Bio, and 1 Reason to Sell Aug 03 / MotleyFool.com - Paid Partner Content |
| Bluebird Bio (BLUE) Reports Q2 Loss, Lags Revenue Estimates Aug 04 / Zacks.com - Paid Partner Content | Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Aug 01 / Zacks.com - Paid Partner Content |
| Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates Aug 04 / Zacks.com - Paid Partner Content | Where Will CRISPR Therapeutics Be in 1 Year? Jul 31 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 5.91 |
| Today’s open | 6.03 |
| Day’s range | 6.03 - 6.96 |
| Volume | 223,146 |
| Average volume (3 months) | 6,227,346 |
| Market cap | $398.0M |
Data as of 11:06am ET, 08/11/2022
Growth & Valuation
| Earnings growth (last year) | -19.50% |
| Earnings growth (this year) | +61.54% |
| Earnings growth (next 5 years) | -64.66% |
| Revenue growth (last year) | -98.54% |
| P/E ratio | NM |
| Price/Sales | 187.99 |
| Price/Book | 1.06 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ALDXAldeyra Therapeutics... | -0.32 | -4.14% |
| ATRAAtara Biotherapeutic... | +0.16 | +3.23% |
| MGTXMeiraGTx Holdings PL... | +0.70 | +7.14% |
| ---- |
Data as of 11:06am ET, 08/11/2022
Financials
| Next reporting date | November 3, 2022 |
| EPS forecast (this quarter) | -$1.12 |
| Annual revenue (last year) | $3.7M |
| Annual profit (last year) | -$819.4M |
| Net profit margin | -15,364.23% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Somerville, Massachusetts |
Forecasts
